horizoncme_horiz_rgb
    • Home
      • Read Articles
        • Current Issue (Issue 4)
        • Issue 3
        • Issue 2
        • Issue 1
      • Categories
        • Editor-in-Chief Column
        • New Drugs
        • Professionalism
        • Financial Resources/Assistance
        • Hematology
        • Solid Tumors
      • Sign Up
    • About Us
      • The Editorial Board
      • Submit an Article
    • Live Conferences
      • APP Oncology Summit
      • Horizon CME
    • Enduring Activities
      • APP Oncology Summit
      • Horizon CME
    Back to home

    HER2

    Solid tumors, New Drugs, Issue4, HER2, Gastric Cancer

    Fam-Trastuzumab Deruxtecan (Enhertu) for HER 2 Amplified Gastric Adenocarcinoma

    Christina Bartholomew Christina Bartholomew

    Although treatment strategies for patients with metastatic gastric cancer who have failed prior lines of therapy remain limited, novel agents such as trastuzumab deruxtecan (Enhertu), provide further options for patients with HER2-positive disease.

    Read more
    horizoncme_logo
    • Default HubSpot Blog